Short-Term Effects of Transdermal Estrogen Replacement Therapy on Coronary Vascular Reactivity in Postmenopausal Women With Angina Pectoris and Normal Results on Coronary Angiograms  by Roqué, Mercè et al.
ENDOTHELIAL FUNCTION
Short-Term Effects of Transdermal Estrogen Replacement Therapy on
Coronary Vascular Reactivity in Postmenopausal Women With Angina
Pectoris and Normal Results on Coronary Angiograms
MERCE` ROQUE´, MD, MAGDA HERAS, MD, EULA`LIA ROIG, MD, MO`NICA MASOTTI, MD,
MONTSERRAT RIGOL, DVM, AMADEU BETRIU, MD, JUAN BALASCH, MD, GINE´S SANZ, MD
Barcelona, Spain
Objectives. This study sought to analyze the effect of short-term
transdermal estradiol treatment on in vivo coronary endothelial
function in postmenopausal women with angina and normal
results on coronary arteriograms.
Background. The incidence of coronary heart disease increases
in women after menopause. Estrogen replacement therapy has
been associated with a global reduction in cardiovascular disease
incidence and mortality. In addition, coronary endothelial dys-
function has been demonstrated in a group of postmenopausal
women. It has been shown that intravenous or intracoronary
estrogens improve endothelial function in postmenopausal women
with coronary atherosclerosis. However, the efficacy of this treat-
ment is unknown in patients with angina and normal coronary
arteries.
Methods. Endothelium-dependent coronary reactivity was ana-
lyzed in 15 postmenopausal women with angina and normal
coronary arteries at baseline and after 24 h of estradiol transder-
mal administration (100 mg).
Results. Estradiol concentration increased from 22 6 8 pg/ml
(mean 6 SEM) at baseline to 76 6 13 pg/ml (p < 0.01) at 24 h. At
baseline, acetylcholine induced vasoconstriction, with a mean
diameter reduction of 223 6 6% (p 5 0.002). After estrogen
treatment, there was no vasoconstriction with acetylcholine, with
a mean diameter change of 0 6 4%, significantly different from the
pretreatment diameter reduction observed (p 5 0.003). Similarly,
estimated coronary blood flow significantly increased in response
to acetylcholine after estrogen treatment, with a mean change of
50 6 30% compared with 5 6 24% before estradiol administration
(p 5 0.04).
Conclusions. Early after transdermal estrogen administration,
endothelium-dependent coronary vasomotion is improved in post-
menopausal women with angina and normal coronary arteries.
(J Am Coll Cardiol 1998;31:139–43)
©1998 by the American College of Cardiology
Despite downward trends in cardiovascular disease mortality
in the recent years, the number of women affected with
cardiovascular disease continues to grow each year (1–4). In
addition, the incidence of coronary heart disease in women
increases dramatically after menopause.
Many women with typical chest pain and ischemic changes
on the exercise test are less likely to have atherosclerotic
coronary lesions than men. This entity, angina pectoris with
angiographically normal coronary arteries, known as syndrome
X, is very heterogeneous. Different hypotheses have been
proposed to explain this syndrome, including endothelial dys-
function and decreased coronary vasodilator reserve (5–9).
Because most patients with syndrome X are postmenopausal
women, a possible link between estrogen deficiency and this
syndrome has been postulated (10).
Several retrospective trials have shown a reduction in
cardiovascular disease incidence associated with the use of
hormone replacement therapy (11). Nevertheless, because
women enrolled in these trials have a higher socioeconomic
status, a possible population bias has been considered by some
investigators (12).
An improvement in endothelium-dependent vasodilation
with short-term estrogen intravenous administration has been
shown both in atherosclerotic epicardial coronary arteries (13)
and in nonatheromatous peripheral vessels (14). However, the
limited experience in postmenopausal women with angina and
normal coronary arteries is controversial (15), and although
oral administration of estrogen is most common, transdermal
estrogen administration has been used as alternative hormone
replacement therapy.
Therefore, the present study sought to analyze the effect of
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transdermal estradiol treatment on coronary endothelial func-
tion in postmenopausal women with angina and normal results
on coronary arteriograms.
Methods
Patients. Fifteen postmenopausal women were recruited
who met the following inclusion criteria: 1) menopause of at
least 1 year in duration, estradiol plasma levels ,30 pg/ml and
follicle stimulating hormone levels .40 IU/liter; 2) typical
chest pain (exercise-induced, constrictive quality) located be-
hind the sternum and radiating to the arms, jaws or back and
relieved by rest or sublingual nitrates; 3) evidence of myocar-
dial ischemia assessed either by electrocardiographic changes
during angina (ST segment depression .1 mm or T wave
inversion on at least two consecutive leads) or with positive
exercise test results; 4) normal results on coronary arterio-
grams. All patients had been referred to our institution for
cardiac catheterization because of recurrent angina despite
antianginal treatment with nitrates and beta-adrenergic block-
ing agents or calcium antagonists.
No patient had ever received hormone replacement ther-
apy.
Patients with a previous history of cardiac disease (myocar-
dial infarction or valvular or myocardial disease) and diabetes
mellitus were excluded. Patients with hypertension and signif-
icant ventricular hypertrophy on the echocardiogram, septum
or posterior wall thickness .12 mm, were also excluded. An
intravenous ergonovine test was performed in patients who
also had rest angina.
All women received accurate information about the study
protocol and gave written consent. The study was approved by
our institution’s ethics committee.
Study protocol. Cardiac catheterization. After diagnostic
catheterization was performed, and the coronary arteriograms
were shown to be angiographically normal and suitable for this
study (minimal baseline coronary artery diameter of 2 mm),
medical treatment was withdrawn for at least 3 half-lives
(between 24 and 48 h) before coronary endothelial function
studies.
The procedure consisted of the placement of a double-
lumen catheter (3F) with a Doppler transducer on the tip
(Schneider) through a 0.014-in. guide wire in the proximal
segment of the chosen coronary artery: left anterior descend-
ing coronary artery in 13 patients and the right coronary artery
in the remaining 2. A graded, 3-min step infusion of increasing
dosages of acetylcholine (Sigma) (1027, 1026, 1025, 1024
mol/liter), followed by 5% dextrose and 40 mg of nitroglycerin,
was selectively performed. Infusions were delivered with a
Harvard infusion pump at a constant rate of 0.8 ml/min. Phasic
and mean coronary blood flow velocity, ECG and arterial
pressure were constantly monitored. At the end of each
infusion, the Doppler mean and phasic flow velocities, ECG
and blood pressure were recorded on a polygraph system
(Micor, Siemens, Germany), and coronary angiography was
performed after injection of 8 ml of nonionic contrast medium
(Iohexol) over 2 s.
A second endothelial function analysis was performed after
24 h of estrogen treatment, following the same protocol.
Results were not available for two patients because of technical
problems. Therefore, comparisons before and after estradiol
administration are confined to the 13 patients with data for
both studies.
Quantitative coronary angiography. Multiple coronary an-
giograms, including angulated views, were recorded on 35-mm
cinefilm (60 frames/s) with a cineangiographic system (Sie-
mens, Erlangen, Germany). The best appropriate view that
allowed optimal visualization was selected for the study.
An end-diastolic frame was selected on the cineprojector,
and the arterial segments were transferred to a digitizer
(ImageComm Systems, Inc.) and analyzed with the videoden-
sitometric analysis system ARTREK (Quantim 20001, QCS
Inc.) previously validated (16). The diameter of the segment of
interest (3 to 4 mm in length) was measured. The diameter of
the empty Judkins catheter was used to calibrate the arterial
diameter in millimeters.
The changes in lumen diameter were measured in the
proximal segment, defined as a segment 3 to 4 mm distal to the
tip of the Doppler catheter.
For ethical reasons, the study lacks a control group. How-
ever, several actions were taken to ensure data quality. 1) In
previous validation studies from this institution, variability of
diameter measurements was analyzed in 13 patients. Coronary
angiograms of nondiseased coronary arteries obtained from
the same patient were obtained 24 h apart. There were no
significant differences between both analyses (baseline diame-
ter: 3 6 0.2 mm; diameter 24 h later: 2.9 6 0.2 mm, p 5 0.56).
2) Intraobserver variability for serial measurements of coro-
nary artery diameter, performed 2 weeks apart by quantitative
coronary angiography, was measured by means of a linear
regression analysis, obtaining an r value of 0.93 (p , 0.0001).
3) Moreover, in the endothelial function analyses, each patient
served as her own control.
Coronary blood flow and coronary vascular resistance mea-
surements. Coronary blood flow was calculated from the prod-
uct of the mean coronary blood flow velocity and the cross-
sectional area of the proximal arterial segment at the tip of the
Doppler catheter and was measured after each intracoronary
infusion. Coronary vascular resistance was estimated from the
coefficient between mean aortic pressure and estimated coro-
nary blood flow.
Estrogen treatment. After the first endothelial function
analysis, a 100-mg patch of estradiol (Estraderm, Ciba) was
applied to each patient for 24 h, until the second study was
performed. We previously observed in 10 patients (data not
Abbreviations and Acronyms
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shown) that peak estradiol levels are achieved within 8 to 10 h
after application of the transdermal patch, and these levels are
maintained at a “plateau” for 36 to 48 h.
Hormone measurements. Blood samples for estradiol, FSH
and nitrate concentrations were obtained before estrogen
administration and at the time of the second coronary endo-
thelial function analysis (24 h apart). Estradiol and FSH levels
were determined using a chemoluminescence immunoenzy-
matic assay (IMMULITE DPC Diagnostic products). Nitrites
and nitrate plasma concentrations were determined using the
Griess reactive method.
Statistical analysis and variables measured. Variables mea-
sured during both catheterizations, at baseline and after estra-
diol treatment, were blood pressure, heart rate and coronary
artery diameter, as well as percent change in diameter over
baseline values, blood flow velocity and estimated coronary
blood flow, with increasing dosages of acetylcholine and nitro-
glycerin. Results are expressed as mean value 6 SE and
percentages, as appropriate. Analysis of variance was used to
analyze the sequential changes in the measured variables and
to compare pretreatment and posttreatment changes. Adjust-
ment for risk factors, including years of menopause, was
performed by means of a multiple regression test. Significance
was accepted at p , 0.05.
Results
Patients. The baseline characteristics of the study patients
are presented in Table 1. The coronary risk factors were
moderate hypertension in nine patients (blood pressure not
.165/95 mm Hg), three of whom had also cholesterol levels
.240 mg/dl; six patients had no risk factors. There were no
smokers in this series. All patients had effort-induced angina,
and seven of them also had angina at rest for an average period
of 4 years. All women had a normal left ventricular ejection
fraction and normal end-diastolic left ventricular pressure. In
eight patients, ischemia was induced during the exercise test,
demonstrated by either ST segment–T wave changes or radio-
nuclide image perfusion defects. Six patients presented with
severe ECG changes, three of whom had persistent anterior
ischemia, with refractory angina with ischemic ECG changes
during the episodes in the other three, which led us to initiate
catheterization. The remaining patient had typical rest chest
pain that was relieved by nitrates but had nonspecific ECG
changes; the ergonovine test result was negative.
Baseline endothelial function analysis. Acetylcholine infu-
sion induced vasoconstriction in 14 patients, with modest
vasodilation in 1. Mean coronary artery diameter progressively
decreased with increasing dosages of acetylcholine (Fig. 1,
Table 2). Mean maximal decrease was 223 6 6% (p 5 0.002).
Nitroglycerin induced normal vasodilation. The estimated cor-
onary blood flow, measured at the point of maximal diameter
change, increased slightly compared with baseline flow, up to
5 6 24% (p 5 NS).
Coronary vascular resistance showed an average increase of
36 6 33% (p 5 NS) compared with baseline values.
Effect of short-term estrogen replacement therapy on coronary
vascular reactivity. Estrogen therapy did not affect blood pres-
sure or heart rate. At the time of the second endothelial
function analysis, acetylcholine induced vasodilation in all
patients except for three, two of whom showed some improve-
ment with respect to the vasoconstriction observed during the
first analysis (from 246% to 229% and from 222% to 210%)
(Table 2). The group mean increase in coronary artery diam-
eter was 0 6 4%, significantly different from the preestradiol
value (p 5 0.003). Nitroglycerin induced a similar vasodilator
response to that observed in the previous analysis. Estimated
coronary blood flow also showed a larger increase after than
before estrogen treatment, with a mean increment of 50 6
30% (p 5 0.04).
Figure 1. Sequential changes in coronary artery diameter with increas-
ing dosages of acetylcholine (Ach) and nitroglycerin (NTG) before and
after estradiol replacement. Dots 5 mean values; vertical bars 5 SEM.
Ach27, Ach26, Ach25, Ach24 5 1027, 1026, 1025, 1024 mol/liter.
Table 1. Baseline Characteristics of Study Patients
History of angina (yr) 4.4 6 5
Range 2 mo–17 yr
Risk factors
Age (yr) 63 6 4
Range 57–68
Menopause (yr) 14 6 6
Range 1–22
Hypertension 8 (64%)
Cholesterol (mg/dl) 230 6 32
HDL cholesterol (mg/dl) 53 6 10
LDL cholesterol (mg/dl) 153 6 10
Triglycerides (mg/dl) 180 6 58
ECG changes
Baseline ECG abnormalities 3/15
ST-T (.1 mm) changes during angina 3/15
No specific T wave changes 1/15
ST depression during exercise test 8/15
LVEDP (mm Hg) 11 6 3
LVEF (%) 61 6 7
*Data presented are mean value 6 SE or number (%) of patients, unless
otherwise indicated. ECG 5 electrocardiographic; HDL 5 high density lipopro-
tein; LDL 5 low density lipoprotein; LVEDP 5 left ventricular end-diastolic
pressure; LVEF 5 left ventricular ejection fraction.
141JACC Vol. 31, No. 1 ROQUE´ ET AL.
January 1998:139–43 ESTRADIOL AND ENDOTHELIAL FUNCTION AFTER MENOPAUSE
Coronary vascular resistance showed an average decrease
of 28 6 13% after estrogen treatment (p 5 NS).
Changes in coronary diameter and blood flow were not
related to the presence or absence of coronary risk factors.
Hormone and nitrite/nitrate measurements. Baseline estra-
diol plasma concentration at baseline was 22 6 8 pg/ml and at
the time of the second analysis, after a 100-mg estradiol patch,
increased up to 76 6 13 pg/ml (p 5 0.0006), well within the
midfollicular phase ovarian cycle physiologic range. Similarly,
nitrite/nitrate plasma levels were 3.6 6 0.3 mmol/liter, which
increased to 5.7 6 1 mmol/liter after estrogen treatment (p 5
NS, n 5 5).
Discussion
The results of this investigation show that in postmeno-
pausal women with angina and normal coronary arteries,
transdermal estrogen replacement has a short-term beneficial
effect on coronary endothelial function. Furthermore, this
effect was observed at 24 h, when estradiol premenopausal
levels were achieved.
The increment in coronary artery diameter and blood flow
in response to acetylcholine after estrogen replacement indi-
cates that endothelium-dependent coronary vascular response
was improved in both resistance and conductance arteries. The
normal response to nitroglycerin, both before and after estro-
gen replacement, suggests that smooth muscle cells retain
normal capacity of vasodilation in postmenopausal women
with angina and normal coronary arteries.
These results are similar to those observed in previous
studies with oral or endovenous administration in patients with
coronary artery disease (13,14). Reis et al. (15) showed similar
results in a group of seven patients with minor coronary
irregularities. However, in eight other patients with normal
results on coronary arteriograms, they could not demonstrate
the presence of endothelial dysfunction or changes with estro-
gen treatment. Differences in patient selection may explain this
discrepancy. Gilligan et al. (17) studied the effect of transder-
mal estrogen treatment on peripheral vascular reactivity in
postmenopausal women treated for 3 weeks, but they could not
measure any significant improvement. We selected patients
with typical angina pectoris despite medical treatment and
ECG evidence of ischemia in the absence of other conditions,
such as coronary spasm or hypertrophy. Therefore, this is a
homogenous group with what is known as syndrome X. We can
speculate that this enhancement in endothelial function may
translate into decreased symptoms, as suggested by Rosano et
al. (18,19), who observed a significant increase in the time to
ST segment depression or total exercise time in patients with
coronary artery disease (18), as well as a reduction in the
number of episodes of chest pain in women with syndrome X
(19).
Potential mechanisms of action of estrogen treatment. Differ-
ent mechanisms of action have been hypothesized to explain
this protective effect. In patients with coronary heart disease,
the beneficial effect of estrogens on lipid profile accounts for
25% to 30% of its protective action (20,21). Estrogen treat-
ment also has a well documented direct effect on vascular
reactivity, but the mechanisms involved are still unclear (22–
27).
It has been suggested (28) that the improvement in vascular
tone might be mediated by the presence, functionalism and
number of estrogen receptors within the vessel wall. However,
it is unlikely that the short-term effect of estrogen on vascular
tone would explain the rapid improvement observed.
The increase in nitrite/nitrate concentration after estrogen
observed in these series, although not significant (we only have
available data for five patients), could reflect an increase in
nitric oxide synthesis in the vascular tree or a decrease in
degradation, possibly due to estrogen action (29,30). In this
regard, it has been hypothesized that the antioxidant effect of
estradiol would reduce the presence of free radicals (superox-
ide anion) and therefore would prevent the inactivation of
nitric oxide (31).
Table 2. Changes in Coronary Diameter, Coronary Blood Flow and Vascular Resistance in Response
to Acetylcholine and Nitroglycerin
Variable Baseline
Acetylcholine
NTG1027 mol/liter 1026 mol/liter 1025 mol/liter 1024 mol/liter
Diameter
Pre 2.5 6 0.2 2.3 6 0.15 2.2 6 0.1 2 6 0.5 1.8 6 0.5 2.7 6 0.6*
Post 2.6 6 0.2 2.5 6 0.7 2.5 6 0.5 2.4 6 0.5 2.4 6 0.5 2.8 6 0.7†
CBF
Pre 263 6 46 215 6 32 290 6 52 273 6 44 285 6 53 531 6 5
Post 359 6 94 440 6 95 471 6 90 515 6 100 572 6 146 564 6 141‡
CVR
Pre 0.59 6 0.1 0.73 6 0.2 0.45 6 0.1 0.58 6 0.1 0.73 6 0.2 0.24 6 0.1
Post 0.31 6 0.1 0.36 6 0.1 0.29 6 0.1 0.28 6 0.1 0.29 6 0.1 0.29 6 0.1
*p 5 0.014, change in diameter with acetylcholine versus baseline, before estrogen treatment. †p 5 0.007, change in
diameter before versus after treatment. ‡p 5 0.003, changes in coronary blood flow (CBF) before versus after treatment.
Data presented are mean value 6 SE. CVR 5 coronary vascular resistance; NTG 5 nitroglycerin; Pre, Post 5 before,
after estrogen administration.
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Conclusions. The present study shows that short-term es-
trogen replacement therapy improves flow-mediated endothe-
lium-dependent vasomotion in postmenopausal women with
angina, normal epicardial coronary arteries and demonstrated
endothelial dysfunction and encourages the design of further
clinical trials.
We thank Roser Casamitjana, MD and the Hormonal Laboratory of our
institution for assistance in the biochemical techniques involved in the present
study.
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